Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer/T cell lymphoma

References

• Sun Z, Ming L, Zhu X, et al. Prevention and control of hepatitis B in China. J Med Virol 2002;67:447–450.
   PubMedGoogle Scholar
• Lau JYN, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993;342:1335–1340.
   PubMed Web of Science ®Google Scholar
• Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007;13:74–81.
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006;15:2078–2085.
   PubMed Web of Science ®Google Scholar
• Nath A, Agarwal R, Malhotra P, et al. Prevalence of hepatitis B virus infection in non-Hodgkin's lymphoma. A systematic review and meta-analysis. Intern Med J 2010;40:633–641.
   PubMed Web of Science ®Google Scholar
• Wang F, Xu R-J, Han B, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 2007;109:1360–1364.
   PubMed Web of Science ®Google Scholar
• Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res 2009;15:2905–2912.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118:6018–6022.
   PubMed Web of Science ®Google Scholar
• Chan JK, Quintanilla-Martinez L, Ferry JA, et al. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 285–288.
   Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Huang H, Lin Z, Lin X, et al. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience. Leuk Lymphoma 2011;52:1041–1048.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer 2013;119:348–355.
   PubMed Web of Science ®Google Scholar
• Chen XQ, Peng JW, Lin GN, et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 2012;29:1237–1241.
   PubMed Web of Science ®Google Scholar
• Wang F, Yuan S, Teng KY, et al. High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance. Eur J Cancer Prev 2012;21:261–267.
   PubMed Web of Science ®Google Scholar
• Kusumoto S, Tanaka Y, Ueda R, et al. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 2011;46:9–16.
   PubMed Web of Science ®Google Scholar
• Li YH, He YF, Jiang WQ, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006;106:1320–1325.
   PubMed Web of Science ®Google Scholar
• Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337: 1733–1745.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Merli M, Rattotti S, et al. Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection. J Clin Oncol 2011;29:e543–e545.
   PubMed Web of Science ®Google Scholar
• De Re V, De Vita S, Marzotto A, et al. Premalignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen driven pathological process. Int J Cancer 2000;87:211–216.
   PubMed Web of Science ®Google Scholar
• Quinn ER, Chan CH, Hadlock KG, et al. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001;98:3745–3749.
   PubMed Web of Science ®Google Scholar
• Zuckerman E, Zuckerman T, Sahar D, et al. bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol 2001;112:364–369.
   PubMed Web of Science ®Google Scholar
• Dewantoro O, Gani RA, Akbar N. Hepatocarcinogenesis in viral hepatitis B infection: the role of HBx and p53. Acta Med Indones 2006;38:154–159.
   PubMedGoogle Scholar
• Lin ZX, Bai B, Cai QC, et al. High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas. Med Oncol 2012;29:3522–3528.
   PubMed Web of Science ®Google Scholar
• Huang CF, Lin SS, Ho YC, et al. The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol 2006;3:97–106.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Liu QF, Wang H, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/ T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012;120:2003–2010.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang WD, Xia ZJ, et al. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Med Oncol 2014;31:860.
   PubMed Web of Science ®Google Scholar